Hansa Biopharma GAAP EPS of SEK -2.56, revenue of SEK 48.1M
Seeking Alpha ·
Hansa Biopharma press release ( HNSBF ): Q2 GAAP EPS of SEK -2.56. Revenue of SEK 48.1M (-2.0% Y/Y) beats by $14.46M. Net cash used in operations: SEK -103.50M. Hansa Biopharma AB (publ) 2026 Q2 - Results - Earnings Call Presentation Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients - Slideshow Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma
AI 시장 분석
Hansa Biopharma reported Q2 GAAP EPS of SEK -2.56 and revenue of SEK 48.1M. Revenue decreased by 2.0% year-over-year but beat estimates by $14.46M, showing a positive surprise. Operating cash flow was recorded at SEK -103.50M, and PAES study results for kidney transplant patients were discussed. Investors should closely monitor the revenue beat factors and ongoing cash burn trends.
상승 영향
- Biotechnology — Q2 revenue beat estimates by $14.46M, recording an earnings surprise and improving investor sentiment.
하락 영향
- Biotechnology — GAAP EPS remained at a loss of SEK -2.56, and ongoing operating cash burn of SEK -103.50M leaves financial burdens.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 46% · Bearish (Short) 54%
359 participants
Related News
- Cleveland-Cliffs Q2 2026 Earnings Preview
- YieldMax Short N100 Option Income Strategy ETF announces weekly distribution of $0.0705
- YieldMax XYZ Option Income Strategy ETF announces weekly distribution of $0.3019
- Intel Earnings Test AI-Fueled Rally
- YieldMax XOM Option Income Strategy ETF announces weekly distribution of $0.0917
- Will Amazon or Microsoft Solve the AI Energy Bottleneck?
